PubMed:32408070
Annnotations
PubMed_ArguminSci
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 130-241 | DRI_Background | denotes | Currently, drug repurposing is an alternative to novel drug development for the treatment of COVID-19 patients. |
| T2 | 242-457 | DRI_Background | denotes | The antimalarial drug chloroquine (CQ) and its metabolite hydroxychloroquine (HCQ) are currently being tested in several clinical studies as potential candidates to limit SARS-CoV-2-mediated morbidity and mortality. |
| T3 | 458-633 | DRI_Background | denotes | CQ and HCQ (CQ/HCQ) inhibit pH-dependent steps of SARS-CoV-2 replication by increasing pH in intracellular vesicles and interfere with virus particle delivery into host cells. |
| T4 | 634-832 | DRI_Background | denotes | Besides direct antiviral effects, CQ/HCQ specifically target extracellular zinc to intracellular lysosomes where it interferes with RNA-dependent RNA polymerase activity and coronavirus replication. |
| T5 | 833-1122 | DRI_Challenge | denotes | As zinc deficiency frequently occurs in elderly patients and in those with cardiovascular disease, chronic pulmonary disease, or diabetes, we hypothesize that CQ/HCQ plus zinc supplementation may be more effective in reducing COVID-19 morbidity and mortality than CQ or HCQ in monotherapy. |
| T6 | 1123-1240 | DRI_Challenge | denotes | Therefore, CQ/HCQ in combination with zinc should be considered as additional study arm for COVID-19 clinical trials. |
LitCovid-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 59-70 | CHEBI:3638;DG_10;CHEBI:3638 | denotes | chloroquine |
| T2 | 71-89 | CHEBI:5801;DG_20;CHEBI:5801 | denotes | hydroxychloroquine |
| T3 | 120-128 | SP_7 | denotes | COVID-19 |
| T4 | 141-145 | CHEBI:23888;CHEBI:23888 | denotes | drug |
| T5 | 185-189 | CHEBI:23888;CHEBI:23888;GO:0017144 | denotes | drug |
| T6 | 223-231 | SP_7 | denotes | COVID-19 |
| T7 | 246-258 | CHEBI:35718;CHEBI:35718 | denotes | antimalarial |
| T8 | 259-263 | CHEBI:23888;CHEBI:23888 | denotes | drug |
| T9 | 264-275 | CHEBI:3638;CHEBI:3638;DG_10 | denotes | chloroquine |
| T10 | 289-299 | CHEBI:25212;CHEBI:25212 | denotes | metabolite |
| T11 | 300-318 | CHEBI:5801;CHEBI:5801;DG_20 | denotes | hydroxychloroquine |
| T12 | 413-423 | SP_7 | denotes | SARS-CoV-2 |
| T13 | 508-518 | SP_7 | denotes | SARS-CoV-2 |
| T14 | 519-530 | GO:0006260 | denotes | replication |
| T15 | 551-564 | GO:0005622 | denotes | intracellular |
| T16 | 565-573 | GO:0031982 | denotes | vesicles |
| T17 | 593-598 | NCBITaxon:10239 | denotes | virus |
| T18 | 695-708 | GO:0005576 | denotes | extracellular |
| T19 | 717-730 | GO:0005622 | denotes | intracellular |
| T20 | 731-740 | GO:0005764 | denotes | lysosomes |
| T21 | 808-819 | NCBITaxon:11118 | denotes | coronavirus |
| T22 | 820-831 | GO:0006260 | denotes | replication |
| T23 | 908-922 | UBERON:0004535 | denotes | cardiovascular |
| T24 | 940-949 | UBERON:0002048 | denotes | pulmonary |
| T25 | 1059-1067 | SP_7 | denotes | COVID-19 |
| T26 | 1215-1223 | SP_7 | denotes | COVID-19 |
hydroxychloroquine
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T1 | 908-930 | Phenotype | denotes | cardiovascular disease | http://purl.obolibrary.org/obo/HP_0001626 |